Tazobactam sodium

This product is a compound preparation, whose components are sterile powders uniformly mixed with piperacillin sodium and tazobactam sodium (the labeled ratio of piperacillin (C23H27N5O7S) to tazobactam (C10H12N4O5S) is 8:1).

1. This product has no synergistic effect with gentamicin against Enterococcus faecalis. It can also have synergistic effect with some cephalosporins against some sensitive strains of Escherichia coli, Pseudomonas aeruginosa, Klebsiella and Proteus. 2. In in vitro tests, this product can inactivate aminoglycosides when used in combination with aminoglycosides. When this product is used in combination with tobramycin, the area under the drug-time curve, renal clearance and urinary excretion of tobramycin will decrease by 11%, 32% and 38% respectively, because piperacillin-tazobactam may inactivate tobramycin. In patients with severe renal insufficiency, such as hemodialysis patients, the pharmacokinetics of tobramycin will change when it is used in combination with piperacillin. 3. This product can prolong the half-life of piperacillin by 21% and the half-life of tazobactam by 71% when used in combination with probenecid. 4. Piperacillin, like carbenicillin, azlocillin, mezlocillin, and ticarcillin, may increase the risk of coagulation disorders and bleeding when used in combination with drugs that can cause hypoprothrombinemia, thrombocytopenia, gastrointestinal ulcers or bleeding. Such as anticoagulants: heparin, coumarin, indandione; non-steroidal anti-inflammatory analgesics, especially aspirin, diflunisal and other salicylic acid preparations, other platelet aggregation inhibitors or sulfinpyrazone. 5. This product cannot be mixed with other drugs in a syringe or infusion bottle. When used with other antibiotics, they must be administered separately. It must not be mixed with solutions containing sodium bicarbonate, and blood products must not be added.

Piperacillin sodium and tazobactam sodium

1. This product has no synergistic effect with gentamicin against Enterococcus faecalis. It can also have synergistic effect with some cephalosporins against some sensitive strains of Escherichia coli, Pseudomonas aeruginosa, Klebsiella and Proteus. 2. In in vitro tests, this product can inactivate aminoglycosides when used in combination with aminoglycosides. When this product is used in combination with tobramycin, the area under the drug-time curve, renal clearance and urinary excretion of tobramycin will decrease by 11%, 32% and 38% respectively, because piperacillin-tazobactam may inactivate tobramycin. In patients with severe renal insufficiency, such as hemodialysis patients, the pharmacokinetics of tobramycin will change when it is used in combination with piperacillin. 3. This product can prolong the half-life of piperacillin by 21% and the half-life of tazobactam by 71% when used in combination with probenecid. 4. Like carbenicillin, azlocillin, mezlocillin, and ticarcillin, when used in combination with drugs that can cause hypoprothrombinemia, thrombocytopenia, gastrointestinal ulcers, or bleeding, piperacillin may increase the risk of coagulation disorders and bleeding. Such as anticoagulants: heparin, coumarin, indandione; nonsteroidal anti-inflammatory analgesics, especially aspirin, diflunisal and other salicylic acid preparations, other platelet aggregation inhibitors or sulfinpyrazone. 5. This product cannot be mixed with other drugs in a syringe or infusion bottle. When used with other antibiotics, they must be administered separately. It must not be mixed with solutions containing only sodium bicarbonate, and blood products and hydrolyzed protein solutions must not be added.